AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23136195
Drug: Rilotumumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab (7.5 mg/kg) plus mitoxantrone and prednisone (MP)
Trial: 23136195
Drug: Rilotumumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab (15 mg/kg) and (7.5 mg/kg)
Trial: 16908789
Drug: Varenicline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1.0 mg twice daily
Trial: 16908789
Drug: Varenicline 0.5
RxNorm normalized name: varenicline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 0.5 mg twice daily
Trial: 16908789
Drug: Varenicline (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (both doses)
Trial: 11759177
Drug: Phospholipid liposomes
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phospholipid liposomes (Liposom Forte) administered intramuscularly (2 ml every other day for 60 days)
Trial: 11759177
Drug: Phospholipid liposomes
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phospholipid liposomes (Liposom Forte) administered intramuscularly
Trial: 9160017
Drug: Factors other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors other than treatment
Trial: 8195354
Drug: Superovulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superovulation with pure follicle stimulating hormone (FSH)
Trial: 3073903
Drug: Monocomponent human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monocomponent human insulin
Trial: 16458316
Drug: 1.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/day niacin
Trial: 11123486
Drug: Baclofen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (40 mg maximum daily dose, given three times a day)
Trial: 11123486
Drug: Clonidine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.8 mg maximum daily dose, given three times a day)
Trial: 9387732
Drug: Injection Salviae
RxNorm normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection Salviae Miltiorrhizae
Trial: 1329919
Drug: Enoxaparin 30
RxNorm normalized name: ENOXAPARIN 30MG/0.3ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 30 mg
Trial: 1329920
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 7500 I.U.
Trial: 1329920
Drug: Both Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Enoxaparin and UF heparin
Trial: 23980693
Drug: Daily interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interruption of sedatives (stopped daily and restarted when COMFORT-behavior score ≥17)
Trial: 23980693
Drug: Daily interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interruption of sedatives
Trial: 18029971
Drug: Chemotherapy (5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (5-FU and adriamycin)
Trial: 16294263
Drug: Risedronate 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 2.5 or 5 mg daily for up to 3 years
Trial: 12131600
Drug: Venlafaxine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (maximum of 150 mg/day)
Trial: 2947149
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg, three tablets daily for two weeks)
Trial: 2947149
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three tablets daily for two weeks)
Trial: 29482596
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Haloperidol and Ketamine
Trial: 10905596
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (3 MU/thrice weekly of alpha-IFN and 1000-1200 mg/daily of ribavirin)
Trial: 10905596
Drug: Alpha-IFN alone
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-IFN alone (3 MU/thrice weekly)
Trial: 8935140
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of stimulant and softening laxatives
Trial: 29293367
Drug: Standard subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard subcutaneous basal‐bolus insulin and blinded CGM (group 1)
Trial: 29293367
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump and blinded CGM (group 2)
Trial: 29293367
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump and nonblinded CGM (group 3)
Trial: 29293367
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (CGM)
Trial: 29293367
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (insulin pump and nonblinded CGM)
Trial: 22990758
Drug: Paced breathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paced breathing twice a day (6 breaths/minute for 15 minutes)
Trial: 18656295
Drug: G-Bond (GC)
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Bond (GC)
Trial: 16647408
Drug: Mixing insulin
RxNorm normalized name: insulin aspart protamine, human / insulin aspart, human Injectable Suspension [NovoLog Mix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixing insulin glargine (IG) with a rapid‐acting insulin (RAI) analogue
Trial: 14662257
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of digoxin and carvedilol
Trial: 14662257
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy to carvedilol alone
Trial: 8806342
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg sublingual nitrate tablet
Trial: 8806342
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg sublingual nitrate spray
Trial: 8806342
Drug: water +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water + 0.3 mg sublingual nitrate tablet
Trial: 8806342
Drug: water +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water + 0.4 mg sublingual nitrate spray
Trial: 31056784
Drug: Online group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online group MBCR during chemotherapy
Trial: 27084721
Drug: ombitasvir/paritaprevir/ritonavir 25/150/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once a day for 12 weeks
Trial: 16988198
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg E2 and 22.5 mg/kg P per day (E2/P)
Trial: 10775867
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolic acid 1% ointment
Trial: 9357096
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine drips (10‐40 micrograms/kg.h) in pediatric patients
Trial: 9357096
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with 8 mg codeine (n = 13) or 30 mg codeine (n = 5) in adult volunteers
Trial: 7691019
Drug: Post-treatment period
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment period (20 days)
Trial: 3779500
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg + saline
Trial: 3779500
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg + metoclopramide 10 mg
Trial: 3779500
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg + saline
Trial: 3779500
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg + metoclopramide 10 mg
Trial: 28263227
Drug: Individualized physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized physical therapy (10 sessions targeting pathoanatomical, psychosocial, and neurophysiological factors)
Trial: 25901479
Drug: FPNS 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPNS 1 × 100 μg
Trial: 25901479
Drug: FPNS 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPNS 2 × 100 μg at 4-hour intervals
Trial: 25901479
Drug: FPNS 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPNS 8 × 100 μg consecutively
Trial: 23719682
Drug: Hydrocodone bitartrate
RxNorm normalized name: Hydrocodone Bitartrate
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hydrocodone bitartrate ER capsules
Trial: 9876334
Drug: Terbutaline (3x5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (3x5 mg/day p.o.)
Trial: 9876334
Drug: Ketotifen (2x1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (2x1 mg/day p.o. for three weeks)
Trial: 2244710
Drug: Nebulized atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized atropine methylnitrate (AMN) + albuterol (ALB)
Trial: 31129917
Drug: Pharmacy care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacy care (medication review, regular dose dispensing, and counselling)
Trial: 28818994
Drug: Diacerein 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein 100 mg/day
Trial: 25938990
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) with vitamins and 5000 IU of dalteparin-sodium for up to 24 weeks' gestation
Trial: 25938990
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received multivitamin pills
Trial: 24121976
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg per day for 6 months (Group 1)
Trial: 19464613
Drug: Dexmedetomidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.0 microg/kg for 10 min, followed by 0.7 microg x kg(‐1) x hr(‐1) continuous infusion)
Trial: 19464613
Drug: Placebo (ESC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ESC of fentanyl = 2 ng/mL)
Trial: 19464613
Drug: Placebo (ESC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ESC of fentanyl = 4 ng/mL)
Trial: 16681478
Drug: Sildenafil (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25, 50, 100 mg, as needed)
Trial: 14872172
Drug: PncDT11 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PncDT11 vaccine
Trial: 11566639
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg PEG-OB protein/wk for 12 weeks
Trial: 8154486
Drug: Dietary protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary protein intake of 1.3 g/kg body weight/d
Trial: 8154486
Drug: Dietary protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary protein intake of 0.575 g/kg body weight/d
Trial: 8154486
Drug: Dietary protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary protein intake of 0.28 g/kg body weight/d (supplemented with amino acids or their keto analogs)
Trial: 1137255
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of prednisone every 8 hours (Group A)
Trial: 1137255
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg of prednisone every morning (Group B)
Trial: 1137255
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of prednisone every other morning (Group C)
Trial: 31184941
Drug: Conventional intraligamentary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intraligamentary injection
Trial: 28200017
Drug: Tailored preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored preventive oral health intervention
Trial: 26317978
Drug: COBAS Amplicor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBAS Amplicor V2, Roche (CA) (lower detection limit 50 IU/ml)
Trial: 26317978
Drug: VERSANT HCV-RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VERSANT HCV-RNA Qualitative Assay, Siemens (TMA) (lower limit detection 10 IU/ml)
Trial: 26317978
Drug: TMA undetectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMA undetectable patients (14 weeks treatment)
Trial: 26317978
Drug: TMA positive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMA positive patients (14 weeks treatment)
Trial: 26317978
Drug: Both CA
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both CA and TMA undetectable (genotype 2, 14 weeks treatment)
Trial: 20187348
Drug: Cetirizine hydrochloride
RxNorm normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine hydrochloride (Zyrtec, 10 mg)
Trial: 11802244
Drug: CPX (8‐cyclopentyl‐1,3‐dipropylxanthine)
RxNorm normalized name: 5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX (8‐cyclopentyl‐1,3‐dipropylxanthine) at doses of 1, 3, 10, 30, 100, 300, and 1,000 mg
Trial: 7747622
Drug: Cumulative intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative intake of aluminum gels
Trial: 2245928
Drug: ASA (Aspirin)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA (Aspirin)
Trial: 6455734
Drug: Physical training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical training (conditioning exercises twice a week for eight weeks)
Trial: 26489804
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg and Ezetimibe 10 mg daily
Trial: 23128915
Drug: Transforaminal (TF)
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal (TF) epidural steroid injection (ESI)
Trial: 23128915
Drug: Interlaminar (IL)
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interlaminar (IL) epidural steroid injection (ESI)
Trial: 21845341
Drug: Strength Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength Training (ST, N = 13, twice a week, 70‐90% 1‐RM)
Trial: 21845341
Drug: Power Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Power Training (PT, N = 15, twice a week, 30‐50% 1‐RM)
Trial: 8894937
Drug: d-sotalol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-sotalol (2 mg/kg IV in 15 min, followed by 1 mg/kg per hour)
Trial: 6152120
Drug: Fansidar (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fansidar (1 tablet a week)
Trial: 29059120
Drug: Daily Engagement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Engagement in Meaningful Activity (DEMA)
Trial: 25461390
Drug: Supplemental vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental vitamin D (4000 IU and 8000 IU) in vitamin D insufficient subjects (serum 25(OH)D<29 ng/mL)
Trial: 22971719
Drug: Two types
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two types of antiplatelet agents (Group I)
Trial: 22971719
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet agent plus warfarin (Group II)
Trial: 21480316
Drug: Long-term low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Long-term low-dose peginterferon therapy
Trial: 21480316
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no peginterferon therapy)
Trial: 19657203
Drug: Therapeutic touch
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic touch (contact on neck and shoulders, delivered twice daily for 3 days)
Trial: 19657203
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (mimic treatment identical in appearance)
Trial: 16445337
Drug: SW and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SW and nonsteroidal anti-inflammatory drugs
Trial: 30719273
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs
Trial: 15789920
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs + Azathioprine
Trial: 23884073
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (pegylated interferon alfa‐2a and ribavirin therapy) without psychoeducation
Trial: 10791186
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg i.v.
Trial: 10791186
Drug: Saline 2
RxNorm normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 2 cc i.v. (Control)
Trial: 9715298
Drug: Intrathecal pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal pethidine 5% (50 mg/ml) 0.5 mg/kg
Trial: 9715298
Drug: 5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lignocaine 1 ml
Trial: 1864086
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone eye drops (tapering dosage)
Trial: 6824996
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) at doses of 0.1 mg, 0.5 mg, and 1.0 mg
Trial: 17945530
Drug: Aliskiren (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (300 mg qd)
Trial: 17945530
Drug: Ramipril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (10 mg qd)
Trial: 16230121
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose heparin (3 x 5000 IU/day for 2 days, then 2 x 5000 IU/day for 12 days, maintenance 5000 IU/day)
Trial: 16230121
Drug: Oral pentosan
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pentosan polysulfate (PPS) alone
Trial: 16230121
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose heparin and oral PPS
Trial: 11850096
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment for 12 weeks
Trial: 11850096
Drug: Oral agents
RxNorm normalized name: DENTAL AND ORAL AGENTS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agents (comparison group)
Trial: 7625338
Drug: Low fat
RxNorm normalized name: Low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat diet (LF) - 20% of energy as fat, 67% as carbohydrate, 13% as protein; 4.80 kJ/g
Trial: 7625338
Drug: Medium fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium fat diet (MF) - 40% of energy as fat, 47% as carbohydrate, 13% as protein; 5.59 kJ/g
Trial: 7625338
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat diet (HF) - 60% of energy as fat, 27% as carbohydrate, 13% as protein; 7.04 kJ/g
Trial: 2199131
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg (+/‐)‐nicardipine
Trial: 150813
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate monohydrate, 411 mg total daily dosage
Trial: 29242413
Drug: Daily assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily assisted physical exercise (one session daily starting from one week of postnatal age, including range-of-motion exercises with gentle compression, flexion and extension of all extremities for 10-15 min)